Shingles vaccine market was estimated to be US$ 2,495.0 million by 2025. It is anticipated to grow at a CAGR of ~17.9% from 2020 to 2030.
Shingles is an infectious disease which is caused by the reactivation of the chickenpox virus or herpes zoster. The common symptoms associated with this infection are development of rashes, ulcers blister and redness on the skin; exhaustion, and itching among others. Vaccines available for the treatment of shingles are Zostavax, Shingrix & SkyZoster, which are manufactured by Merck & Co., Inc., GlaxoSmithKline plc & SK chemicals respectively.
Major Key Players of the Shingles Vaccine Market are:
GlaxoSmithKline plc., and Merck & Co., Inc.. and SK Chemicals
No comments:
Post a Comment